SONY

Product Data Sheet

Brilliant Violet 605™ anti-mouse CD69

Catalog # / Size: 1122645 / 125 µl
1122650 / 50 µg

Clone: H1.2F3

Isotype: Hamster IgG

Immunogen: Mouse dendritic epidermal T cell line Y245

Reactivity: Mouse

Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 605™ and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Concentration: microg sizes: 0.2 mg/ml
microL sizes: lot-specific



PMA+ionomycin-stimulated (6 hours) C57BL/6 mouse splenocytes were stained with CD69 (clone H1.2F3) Brilliant Violet 605™ (filled histogram).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the microg size, the suggested use of this reagent is ≤0.5 microg per million cells in 100 microL volume. For immunofluorescent staining using the microL size, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes: The H1.2F3 antibody has been reported to augment T cell activation. Additional reported applications (for the relevant formats) include: *in vitro* T cell and NK cell activation[1-3], immunohistochemistry[4,5], and immunoprecipitation1.

This antibody has been characterized in the literature as containing a λ (λ) light chain.

Application References:
1. Yokoyama WM, *et al.* 1988. *J. Immunol.* 141:369. (IP)
2. Sobel ES, *et al.* 1993. *J. Immunol.* 150:673.
3. Karlhofer FM, *et al.* 1991. *J. Immunol.* 146:3662.
4. Zhou X, *et al.* 2005. *J. Biol. Chem.* 280:31240. (IHC)
5. Podd BS, *et al.* 2006. *J. Immunol.* 176:6532. (IHC)
6. Lawson BR, *et al.* 2007. *J. Immunol.* 178:5366.
7. Lee JW, *et al.* 2006. *Nature Immunol.* 8:181.
8. Epardaud M, *et al.* 2008. *Cancer Res.* 15:2972. PubMed
9. Jordan JM, *et al.* 2008. 76:3717. PubMed
10. Kenna TJ, *et al.* 2008. *Blood* 111:2091. PubMed
11. Ishikawa C, *et al.* 2013. *Biochim Biophys Acta.* 167:99. PubMed

---

Description: CD69 is a 60 kD type II membrane protein composed of a 27/33 kD disulfide-linked homodimer, also known as Very Early Activation Antigen (VEA), AIM, EA1, MLR3, and gp34/28. It is expressed on a subset of thymocytes and platelets. CD69 is rapidly induced on activated T and B cells, neutrophils, and NK cells. It is a C-type lectin, closely related to the NKR-P1 and Ly-49 NK cell activation molecules. CD69 is involved in the early events of cell activation and thymocyte positive selection.

Antigen References:
1. Barclay AN, *et al.* 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Testi R, *et al.* 1994. *Immunol. Today* 15:479.
3. Moretta A, *et al.* 1991. *J. Exp. Med.* 174:1393.
4. Yokoyama WM,